The lesser toxicity of the 20 mg/m2 dose compared with the 25 mg/m2 dose may benefit frail patients in particular, or those with poor functional status.
The thromboSeq test result might not only provide information regarding lung cancer diagnostics, but potentially any other tumor types as well, and may enable tumor-type stratification.
As patients become older, additional factors must be considered in planning their treatment.
Extramedullary multiple myeloma is increasingly encountered in the clinic and most patients will need aggressive treatment.
CDK4/6 Inhibitors in Breast Cancer Treatment: Recent Research, Safety Profiles, Acquired Resistance, Next Steps
Breast tumors can become resistant to CDK 4/6 inhibitors, but improved understanding of the mechanisms of acquired resistance might point to additional treatment strategies.
Volatile Organic Compounds and Esophageal Cancer: Understanding the Implications for Diagnosis and Treatment
While utilization of VOCs in the early detection of esophageal cancer has shown promise, future studies should aim at determining which VOCs would be the most specific in diagnosing GI malignancies.
A new study finds some hopeful signs of progress in understanding blast phase CML, which is typically associated with poor outcomes.
Hereditary kidney cancer syndromes are often diagnosed by astute clinicians who recognize that there is more to a patient's diagnosis then just the random event of getting cancer.
Not conducting a second tissue biopsy could have dangerous implications for the patient according to a recent article.
An emerging approach in the early stages of clinical development for MM is oncolytic virotherapy, in which viruses are used to eliminate cancer cells directly or indirectly.
CTA spoke with Calvin Chao, MD, about how the Oncotype DX® test is implemented, how results can guide treatment, its use globally, and the future of prognostic testing.
Durvalumab's optimal clinical role in managing lung cancer remains unclear and more robust predictive biomarkers are needed.
As more experience with sirolimus has been gained, it began to be used "off-label" to prevent rejection in multiple transplant recipients and is now being studied in the treatment of GVHD.
Clinicians continue to learn about which patients will benefit most from different immunotherapy treatments, and how dosing can effect adverse events.
There are estimated to be 13 distinct hereditary renal cell carcinoma (RCC) syndromes, each of which is associated with specific germline mutations, including von Hippel-Lindau disease (VHL).
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- beta-Carotene and Cancer
- Novel Therapeutic Target in Chronic Lymphocytic Leukemia Cells Identified
- Venetoclax Plus Rituximab May Prolong Progression-free Survival in CLL
- Lower Cabazitaxel Dose May Benefit Patients With Prostate Cancer
- Different Types of Obesity May Increase Risk of Breast Cancer Subtypes